— · NSE/BSE: PIRAMAL ENTERPRISES
PIRAMAL ENTERPRISES
Market Cap —
Verdict: Average
Quality Scores
Multi-Bagger
68/100
Compounder Quality
62/100
Management Credibility
78/100
Governance
85/100
Cash Flow Quality
70/100
AI Summary
Piramal Enterprises (PEL) has undergone a massive structural transformation from a diversified conglomerate into a focused Non-Banking Financial Company (NBFC). The sale of its core healthcare business to Abbott in 2010 and the subsequent demerger of the pharma business in 2022 have completely redefined the corporate identity. While the group is led by the visionary Ajay Piramal, the transition phase has been marked by significant volatility in earnings and asset quality. The acquisition of DHFL was a pivotal moment in its strategy to balance its wholesale-heavy book with retail lending.…
Top Opportunities
- Successful demerger of Pharma business unlocking value
- One of the largest NBFCs in India with diverse presence
- Significant reduction in wholesale lendeing exposure
Top Risks
- Concentrated exposure to legacy wholesale real estate loans
- Impact of RBI AIF circular leading to high provisions
- Net loss reported in FY24 due to one-offs
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.